Tisdag 26 November | 06:36:13 Europe / Stockholm
Svenska | English

Asarina Pharma

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2024-08-21 - Extra Bolagsstämma 2023
2024-06-20 - Årsstämma
2024-05-17 - X-dag ordinarie utdelning ASAP 0.00 SEK
2024-02-27 - Bokslutskommuniké 2023
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-23 - X-dag ordinarie utdelning ASAP 0.00 SEK
2023-05-22 - Årsstämma
2023-02-27 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-05 - X-dag ordinarie utdelning ASAP 0.00 SEK
2022-05-04 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-11-25 - 15-10 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-18 - Kvartalsrapport 2021-Q1
2021-04-22 - X-dag ordinarie utdelning ASAP 0.00 SEK
2021-04-21 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-25 - Kvartalsrapport 2020-Q3
2020-08-19 - Kvartalsrapport 2020-Q2
2020-05-26 - Kvartalsrapport 2020-Q1
2020-05-06 - X-dag ordinarie utdelning ASAP 0.00 SEK
2020-05-05 - Årsstämma
2020-02-21 - Bokslutskommuniké 2019
2020-01-21 - Extra Bolagsstämma 2019
2019-11-20 - Kvartalsrapport 2019-Q3
2019-08-20 - Kvartalsrapport 2019-Q2
2019-05-20 - Kvartalsrapport 2019-Q1
2019-05-09 - X-dag ordinarie utdelning ASAP 0.00 SEK
2019-02-25 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Asarina Pharma är ett svenskt läkemedelsbolag med fokus på läkemedel för kvinnors hälsa. Bolagets huvudprodukt, som är under utveckling, är Sepranolone. Sepranolone är avsett för behandling av PMDD, den allvarligaste formen av Premenstruel stress (PMS). Verksamhet innehas runtom den nordiska marknaden. Asarina Pharma har sitt huvudkontor i Solna, Sverige.
ASARINA PHARMA AB (PUBL) RELEASES ANNUAL REPORT 2023
2024-06-04 22:54:00

(Stockholm, 4 June 2024) Asarina Pharma (“the Company”) today announces the release of its 2023 Annual Report.

Status and Outlook
Since completing the phase IIa study in April 2023, the Company has focused on finding a partner who can bring Sepranolone into the next clinical phase. The Company will continue to explore the potential for a partnership, i.e. a sale or out-licensing of its IP assets.

The Company believes that it can complete the partnering process with its current financial resources but there is no guarantee that it will not incur unexpected costs during this partnering process. In case of an unfavorable outcome of the partnering activities, the Company will initiate an orderly winding-down, which may include the sale of assets and/or liquidation.

The full Annual Report 2023 including CEO Statement and consolidated financial statements with notes is available on the Company’s website here:
https://asarinapharma.com/investors/financial-reports/

For further information, please contact:
Peter Nordkild, CEO, Asarina Pharma AB
Phone: +45 25 47 16 46
E-mail: peter.nordkild@asarinapharma.com

Jakob Dynnes Hansen, CFO, Asarina Pharma AB
Tel: +45 5132 3698
E-mail: jakob.dynnes@asarinapharma.com

The Company’s Certified Adviser is Carnegie Investment Bank AB (publ)

About Asarina Pharma
Asarina Pharma is a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive Compulsive Disorder that still lack safe, efficacious pharmaceutical treatments.

Attachments
Asarina Pharma Annual Report 2023 EN Master

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden